Health Care · Pharmaceutical Preparations

DMAC DiaMedica Therapeutics Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 140104065 filings
Russell 2000

DMAC at a glance

DiaMedica Therapeutics Inc. (DMAC, SEC CIK 1401040) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding DiaMedica Therapeutics Inc. (DMAC) shares worth $44.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
20 funds
$44.7M · −1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • R&D expenses $9.2M vs $6.4M YoY, G&A expenses $2.4M vs $2.6M
  • Net loss $31.5M for nine months vs $24.0M YoY, no margin figures disclosed
  • Cash, equivalents and securities $34.9M vs $59.9M at December 31, 2025
  • ReMEDy2 enrollment slower than expected, interim results expected by end of Q1 2027; additional funding anticipated

Risk Factors

  • No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
  • Carried-forward risk: unknown or currently immaterial risks could impair business, financial condition, or results of operations
  • Carried-forward disclosure: existing uncertainties could cause actual results to differ materially from forward-looking statements

AI summary of the DMAC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • FGR enrollment complete for first two cohorts, 12 participants at 5 and 10 µg/kg, with preliminary topline results scheduled November 24
  • ReMEDy2 stroke trial exceeded 200 participants, enabling DSMB interim analysis after 90-day follow-up, expected Q1 2027
Filed Aug 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full condensed financial results available in Exhibit 99.1, relevant for assessing liquidity and operating performance

Item EX-99.1: Item EX-99.1

  • Q2 net loss $10.1M, up from $7.7M, with R&D expense rising to $8.2M from $5.8M
  • Cash, equivalents and investments $43.5M, down from $59.9M at December 31, 2025, supporting planned operations through 2027
Filed May 21, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All seven incumbent directors re-elected, preserving board continuity through the next annual meeting
  • Baker Tilly US, LLP ratified as independent auditor for fiscal 2026, with shareholders authorizing board-set remuneration

AI summaries of DMAC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DMAC

Don't miss the next DMAC filing

  • Alerts as it files. A push when DMAC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DMAC, by share count.
  • Ask anything. An AI agent that reads every DMAC filing and answers with sources.

DMAC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Pauls Dietrich JohnAAug 10, 2026-
Kellen ScottAJun 1, 2026-
Parsons James T.AJun 1, 2026-
Giuffre Randall MichaelAJun 1, 2026-
Kuntz RichardAJun 1, 2026-
Krop JulieAJun 1, 2026-
Lewis TanyaAJun 1, 2026-
O'Connor Daniel J.AJun 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$21.3M-$26.7M-$34.4M
Net Income-$19.4M-$24.4M-$32.8M
Balance Sheet
Total Assets$54.2M$46.3M$61.4M
Equity$51.1M$40.7M$56.1M
ROE-38.0%-60.0%-58.4%
Per Share
EPS-$-0.60$-0.70
Cash Flow
Operating CF-$18.7M-$22.1M-$29.1M
CapEx$24K$25K$40K

Source: XBRL data in DiaMedica Therapeutics Inc. (DMAC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DMAC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DMAC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$44.7M
Q2 202621$37.8M
Q1 202622$33.5M
Q4 202520$43.6M
Q3 202520$36.5M
Q2 202516$14.6M
Q1 202512$8.6M
Q4 20248$9.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 139 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DMAC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Aug 12, 2026--
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
8-KMay 21, 2026Analysis
8-KMay 6, 2026Analysis
10-QMay 6, 2026Analysis
8-KMar 31, 2026--
10-KMar 30, 2026-
4Jan 6, 2026-
4Jan 6, 2026-
4Jan 6, 2026-
8-KJan 5, 2026-
8-KDec 18, 2025-
4Dec 8, 2025-

Related Health Care companies

All Health Care →

DMAC SEC filings: frequently asked questions

Which institutions hold DMAC stock?

As of September 30, 2026, the largest DiaMedica Therapeutics Inc. (DMAC) holders among the 13F filers tracked by SignalX were BlackRock ($18.3 million), Millennium Management ($6.9 million), State Street Corp ($5.5 million), Vanguard Capital Management LLC ($3.0 million), Northern Trust ($2.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did DMAC report in its latest 8-K?

DiaMedica Therapeutics Inc. (DMAC) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest DMAC SEC filings?

DiaMedica Therapeutics Inc. (DMAC) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 12, 2026.

What is DMAC's SEC CIK number?

DiaMedica Therapeutics Inc. (DMAC)'s SEC Central Index Key (CIK) is 1401040. EDGAR lists every DMAC filing under that number.

Ask anything about DMAC

The research agent reads DMAC's filings, financials, insider trades and 13F holders, then answers with sources.